17/03/2016

Biohit Oyj

Biohit and Tianjin Jingsheng Biological Technology Development Co. Ltd. to start co-operation

Biohit Oyj and Tianjin Jingsheng Biological Technology Development Co. Ltd have signed a distributor agreement for the distribution of the Biohit Calprotectin ELISA test in China.

Biohit Calprotectin test is a useful quick test for measuring calprotectin in a stool sample. The test is used to differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) as well as in monitoring of the treatment in IBD patients. Inflammatory bowel diseases are Crohn's disease and ulcerative colitis, diagnosed increasingly. Particularly ulcerative colitis is linked with an increased risk of colon cancer.

The test measures calprotectin released from the inflamed intestinal mucosa into faeces. Calprotectin is derived from the inflammatory cells, and its concentration in the faeces reflects the activity of the inflammation and the efficacy of the treatment in IBD patients. In patients with IBS, this test is usually negative.

General Director Zeng Zhao Hong, Tianjin Jingsheng Biological Technology Development Co. Ltd.:  'In China there seems to be differences in prevalence of IBD between rural and urban population. The disease is increasing particularly among young people. Fecal calprotectin is an emerging biomarker of gut inflammation. Biohit Calprotectin test differentiates reliably IBD and IBS and reduces significantly the need of colonoscopies.'

CEO Semi Korpela, Biohit Oyj: ‘We are starting a co-operation with Tianjin Jingsheng Biological Technology Development Co. Ltd in the large Chinese market. We have started the registration in China required to obtain the marketing authorisation for the product.'
 

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
 

Tianjin Jingsheng Biological Technology Development Co. Ltd in brief

Tianjin Jingsheng Biological Technology Development Co. Ltd. (TJJS) is a globally operating immunoassay and molecular biology company. TJJS is located in China. For over 20 years, TJJS has continuously marketed immunoassay kits, biochemical reagents, PCR products, cytopathological test reagents and instruments. TJJS offers professional and timely after-sales service. The customers of TJJS can be found all over Asia. www.jsbiotech.com

Exhibitor Data Sheet